<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01594268</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001AKR10</org_study_id>
    <nct_id>NCT01594268</nct_id>
  </id_info>
  <brief_title>A Prospective, Open Label Study of CERtican in KIdney Transplantation</brief_title>
  <acronym>CERKI</acronym>
  <official_title>A Prospective, Open-label Study to Assess Safety of Certican in Kidney Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      A prospective, open label study of CERtican in KIdney transplantation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with serious adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>frequency of serious adverse event</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Kidney Transplant</condition>
  <arm_group>
    <arm_group_label>Kidney transplantation patient</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Kidney transplantation patient; single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>A prospective, open-label study to assess safety of Certican in kidney transplant patients</description>
    <arm_group_label>Kidney transplantation patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria: (Each patient must meet all of the following criteria.)&#xD;
&#xD;
          1. Males and females aged 20-65 years inclusive (in Korean age) who is scheduled to&#xD;
             receive a primary kidney transplant.&#xD;
&#xD;
          2. Patients who received explanation of the study overview and signed on the informed&#xD;
             consent form of this study.&#xD;
&#xD;
          3. de novo patients who are going to receive a kidney transplant from a deceased (cold&#xD;
             ischemic time (CIT) &lt; 36 hours), living unrelated or related donor&#xD;
&#xD;
        Exclusion criteria (Any patient who meets any of the following criteria will not be able to&#xD;
        participate in the study.)&#xD;
&#xD;
          1. Multi-organ transplant recipients (e.g. simultaneous kidney-pancreas transplant) or&#xD;
             patients who previously received an organ transplant other than a kidney transplant&#xD;
&#xD;
          2. Patients who are scheduled to receive a kidney transplant from a zero-antigen&#xD;
             mismatched donor, bilateral kidney donor, a non-heart beating donor or a donor aged&#xD;
             over 60 years&#xD;
&#xD;
          3. Patients who should avoid potential exposure to everolimus due to acute or chronic&#xD;
             severe allergy treatment or patients who have hypersensitivity to everolimus and drugs&#xD;
             of similar chemical classes (e.g. macrolides)&#xD;
&#xD;
          4. Class 1 PRA&gt;30% by CDC-based assay or Class 1 PRA&gt;50% by flow cytometry or EIA&#xD;
&#xD;
          5. Recipients of a kidney from a ABO-incompatible live-donor or T-cell cross&#xD;
             matching-positive donor&#xD;
&#xD;
          6. Thrombocytopenia&lt;75,000/mm3, absolute neutrophil count&lt;1,500/mm3, and/or&#xD;
             leukopenia&lt;4,000/mm3&#xD;
&#xD;
          7. Severe hypercholesterolemia (350mg/dl) or hypertriglyceridemia (&gt;500mg/dl) (However,&#xD;
             patients with controlled hyperlipidemia are eligible for the study.)&#xD;
&#xD;
          8. Use of other investigational drugs for 30 days before enrollment in the study&#xD;
&#xD;
          9. History of malignancy of any organ system (other than localized basal cell carcinoma&#xD;
             of the skin), treated or untreated, within the past 5 years before enrollment in the&#xD;
             study, regardless of whether there is evidence of local recurrence or metastases&#xD;
&#xD;
         10. Pregnant or nursing women, and women of child-bearing potential who have a plan to be&#xD;
             pregnant or do not consent to select an appropriate method of birth control (e.g. oral&#xD;
             contraceptives, hormone implant, IUD, diaphragm barrier, condom, abstinence, etc.)&#xD;
             (women of child-bearing potential means women less than 2 years post-menopausal or not&#xD;
             having hysterectomy or surgical management, i.e. bilateral tubal ligation or bilateral&#xD;
             oophorectomy)&#xD;
&#xD;
         11. Presence of surgery or medical condition (except for current transplant) which may&#xD;
             change absorption, distribution, metabolism, and excretion of the investigational&#xD;
             product at the investigator's discretion and/or severe diarrhea, active&#xD;
             gastrointestinal disease or uncontrolled diabetes&#xD;
&#xD;
         12. Patients who are HIV-, HCV-, and HBV positive&#xD;
&#xD;
         13. Recipients of an organ from a donor who is HBsAg-, HCV-, and HIV-positive&#xD;
&#xD;
         14. Evidence of drug or alcohol abuse&#xD;
&#xD;
         15. Severe restrictive or obstructive pulmonary disease&#xD;
&#xD;
         16. Patients with severe liver disease (AST, ALT or total bilirubin&gt;2.5 times ULN&#xD;
             including abnormal liver function test)&#xD;
&#xD;
         17. Patients with severe systemic infection requiring continuous therapy which may&#xD;
             influence the objectives of the study at the investigator's discretion&#xD;
&#xD;
         18. Patients in whom continuous treatment may lead to clinically serious infection at the&#xD;
             investigator's discretion or patients with other severe surgery complications or&#xD;
             problems with continuous wound treatment&#xD;
&#xD;
         19. Patients who have a genetic problem including galactose intolerance, lapp lactase&#xD;
             deficiency, and glucose-galactose malabsorption&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>738-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suwon</city>
        <zip>442-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>May 4, 2012</study_first_submitted>
  <study_first_submitted_qc>May 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2012</study_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney transplant</keyword>
  <keyword>Certican</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

